消风散加味对慢性持续期支气管哮喘患者FeNO,血浆SP和VIP含量的影响

贾琳; 武蕾; 郭洁; 观云

doi:10.13422/j.cnki.syfjx.20182030

您当前的位置：

首页 >

文章列表页 >

消风散加味对慢性持续期支气管哮喘患者FeNO,血浆SP和VIP含量的影响

临床 | 更新时间：2024-09-23

- 消风散加味对慢性持续期支气管哮喘患者FeNO,血浆SP和VIP含量的影响
- Effect of Modified Xiaofengsan on FeNO,SP and VIP in Plasma in Persistent Asthma Patients
- 中国实验方剂学杂志 2018年24卷第22期页码：148-152
- 作者机构：
- 作者简介：
- 基金信息：
  
  河北省科技计划项目（16277726D）;河北省中医药管理局课题项目（2016032）;河北省中医药类重大医学科研课题项目（zyzd2013001）
- DOI：10.13422/j.cnki.syfjx.20182030
  中图分类号： R259
- 纸质出版日期：2018
- 稿件说明：
移动端阅览
贾琳, 武蕾, 郭洁, 等. 消风散加味对慢性持续期支气管哮喘患者FeNO,血浆SP和VIP含量的影响[J]. 中国实验方剂学杂志, 2018,24(22):148-152.

JIA Lin, WU Lei, GUO Jie, et al. Effect of Modified Xiaofengsan on FeNO,SP and VIP in Plasma in Persistent Asthma Patients[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(22): 148-152.
贾琳, 武蕾, 郭洁, 等. 消风散加味对慢性持续期支气管哮喘患者FeNO,血浆SP和VIP含量的影响[J]. 中国实验方剂学杂志, 2018,24(22):148-152. DOI： 10.13422/j.cnki.syfjx.20182030.

JIA Lin, WU Lei, GUO Jie, et al. Effect of Modified Xiaofengsan on FeNO,SP and VIP in Plasma in Persistent Asthma Patients[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(22): 148-152. DOI： 10.13422/j.cnki.syfjx.20182030.

摘要

目的：观测消风散加味对慢性持续期支气管哮喘呼出气一氧化氮浓度（fractional concentration of exhaled nitricoxide，FeNO），血浆P物质（substance P，SP）和血管活性肠肽（vasoactive intestinal peptide，VIP）含量的影响，探讨其治疗支气管哮喘的可能作用机制。方法：选取符合纳入标准的支气管哮喘患者80例，随机分为对照组和治疗组。对照组给予布地奈德福莫特罗粉吸入剂（160 μg/4.5 μg），早晚各2吸。治疗组在对照组治疗的基础之上给予消风散加味，每日1剂。两组疗程均为1个月。观察治疗前后两组患者肺功能相关指标第1秒末用力呼气量（forced expiratory volume in first second，FEV1），第1秒末用力呼气量占用力肺活量百分比（percentage of forced expiratory volume in first second and forced vital capacity，FEV1/FVC），1 s用力呼气量占预计值百分比（percentage of forced expiratory volume in first second and its predicted value，FEV1%），呼气流量峰值变异率（variety ratio of peak expiratory flow，PEF），FeNO，血浆SP，VIP水平变化，并记录两组患者不良反应。结果：治疗后两组患者肺功能指标FEV1，FEV1/FVC，FEV1%比较，治疗组均高于对照组（P<0.05）；PEF变异率比较，治疗组低于对照组（P<0.05）；治疗后治疗组患者FeNO，血浆SP水平均低于对照组（P<0.05），治疗组VIP水平高于对照组（P<0.05）；两组患者不良反应总发生率比较，治疗组低于对照组（P<0.05）。结论：消风散加味联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘与单用布地奈德福莫特罗粉吸入剂治疗相比较，可更有效改善支气管哮喘患者的肺功能，调节神经源性气道炎症水平，同时降低不良反应发生率，值得推广应用。

Abstract

Objective:To observe the effect of modified Xiaofengsan on fractional concentration of exhaled nitricoxide (FeNO)

substance P (SP) and vasoactive intestinal peptide (VIP) in plasma of patients with persistent asthma. Method:Totally 80 cases in line with the inclusion criteria were collected and randomly divided into control group and treatment group. Patients in control group were given Budesonide/formoterol(160 μg/4.5 μg)

while patients in treatment group were given modified Xiaofengsan combined with Budesonide/formoterol for 1 months. Before and after treatment

forced expiratory volume in first second(FEV1)

percentage of forced expiratory volume in first second and forced vital capacity(FEV1/FVC)

percentage of forced expiratory volume in first second and its predicted value(FEV1%)

variety ratio of peak expiratory flow

FeNO and the levels of SP and VIP in plasma were measured respectively. The adverse reactions of the two groups were recorded at the same time. Result:Compared with control group

FEV1

FEV1/FVC

FEV1%

VIP in plasma in treatment group were higher(P<0.05)

while PEF variety ratio

FeNO and the level of SP in plasma were lower (P<0.05)after treatment. Compared with control group

the incidence rate of the adverse reactions in treatment group was lower (P<0.05). Conclusion:Modified Xiaofengsan combined with Budesonide/formoterol is more effective than Budesonide/formoterol in improving pulmonary function

regulating the neurogenic airway inflammation and lowering the incidence rate of the adverse reactions. It is worth promotion and application.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

固本防哮饮对IL-4联合IL-13诱导的人支气管上皮细胞中CGRP/ILC2及GABA表达的影响

基于TGF-β₁/Smad3信号通路探讨益气温阳护卫汤防治支气管哮喘的作用机制

中医药调控氧化应激相关信号通路防治支气管哮喘研究进展

益气温阳护卫汤调控PI3K/Akt/mTOR自噬途径治疗支气管哮喘大鼠机制

疏风通络方对哮喘小鼠模型Eotaxin、CCR3蛋白表达及ERK磷酸化的影响